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The 2-nitroimidazole analogs are known to have an interesting property, namely, they 
accumulate selectively in hypoxic tissue.  The mechanism for the intracellular retention in 
hypoxic cells is not fully understood.  It is believed that 2-nitroimidazoles undergo 
nitro-reduction with the formation of products that bind to intracellular elements and remain 
trapped in hypoxic tissues1).  18F-Fluoromisonidazole (18F-FMISO) was the first such 
radiopharmaceutical developed, and was used most widely for imaging hypoxia. However, 
misonidazole is a rather lipophilic compound, and the images of 18F-FMISO may have a low 
target-to-background ratio.  Therefore, there is ongoing research to develop better compounds 
for clinical use.  18F-FRP170, 1-(2-fluoro-1-[hydroxymethyl]ethoxy)- methyl-2-nitroimidazole, 
is a new hypoxia imaging agent for positron emission tomography (Fig. 1).  This compound 
was synthesized by 18F-labeling of RP170, which was developed as a new hydrophilic 
2-nitroimidazole analog2,3).  In the present study, we analyzed dynamic whole-body imaging in 
healthy volunteers and dynamic tumor imaging in three patients with lung cancer. 
 
Methods 
Four healthy male volunteers and three lung cancer patients were enrolled in this study.  
Volunteers underwent dynamic whole-body scans just after injection of 18F-FRP170 for about 
90 min, while the lung cancer patients underwent dynamic tumor imaging for about 60 or 120 
min.  Data are expressed as standardized uptake values (SUV). Regions of interest were placed 
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over images of each organ or tumor to generate time–SUV curves. 
 
Results 
The series of dynamic whole-body scans showed rapid elimination of 18F-FRP170 from 
the kidneys following elimination from the liver.  Figure 2 shows a series of dynamic 
whole-body images of a 32-year-old male volunteer.  Very low physiological uptake was 
observed above the diaphragm.  18F-FRP170 uptake in the lung cancer lesion could be 
visualized clearly from early after injection.  The changes of tumor SUV, tumor/blood ratio, or 
tumor/muscle ratio about 30 min. after injection or later were small.  Figure 3 shows 
18F-FRP170 images acquired 1 hr and 2 hr after injection in patient with lt. lung cancer.  The 
tumor/muscle ratio and tumor/blood ratio were 1.69 and 1.09 at 1 h after injection, and 1.96 and 
1.24 at 2 h, respectively.  
 
Discussion 
Since the 1990s, there have been many intensive studies using 18F-FMISO, and a great 
deal of research effort has been directed toward synthesizing new hypoxia markers that 
overcome the limitations of 18F-FMISO.  Compounds characterized by high hydrophilicity 
were thought to be better for imaging hypoxia because of rapid blood clearance and high 
target-to-background ratio.  Therefore, many 2-nitroimidazole analogs have been developed by 
changing the side chain of the drug.   18F-FRP170 is designed as a hydrophilic 
2-nitroimidazole analog, and is also expected to yield images with high contrast and a low 
background level.  In the volunteer study, 18F-FRP170 showed rapid elimination from almost 
all organs via excretion through the urinary pathway. In addition, its excretion into the bile was 
delayed.  These observations were thought to be due to the high degree of hydrophilicity of the 
tracer.   18F-FRP170 uptake in the lung cancer could be visualized clearly from early after 
injection.  The tumor/muscle ratio tended to decrease slightly prior to 45-60 min after injection, 
but then tended to increase slightly.  On the other hand, the tumor/blood ratio showed a rapid 
increase prior to about 30 min after injection, after which it increased gradually with time.  
The tumor/muscle ratio and tumor/blood ratio in Fig 3 were 1.69 and 1.09 at 1 h after injection, 
and 1.96 and 1.24 at 2 h, respectively.  Both the tumor/muscle and tumor/blood ratios were 
higher 2 h than 1 h after injection, although the differences were too small to detect visually.  
The images obtained about 60 min after injection may be of sufficient quality to allow 
evaluation of tumor uptake in a clinical setting.  However, considering the recent advances of 
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PET technology, the images of 18F-FRP170 demonstrated in the present study may have room 
for improvement.  For example, increasing injected doses, longer emission-scan time, or using 
the latest PET/CT scanner may improve the image quality.  The 2-nitroimidazoles are known 
to enter the cells by passive diffusion; therefore, their intracellular uptake is thought not to be 
particularly high.  It may be necessary to administer a larger amount of radioactivity than that 
used in the present study. From the standpoint of estimated radiation dose4), about 370–555 
MBq of 18F-FRP170 may be considered safe for use in adults. 
Conclusions: We analyzed dynamic 18F-FRP170 images obtained in healthy volunteers 
and in three patients with lung cancer. Rapid elimination of the tracer from the kidney was seen 
in the volunteers, supporting the strong hydrophilicity of 18F-FRP170.  The images obtained in 
the cases of the lung cancer patients demonstrated good image contrast even at 1 h after 
injection.  18F-FRP170 could be expected to yield good tumor images and allow scanning to 
begin early, but further investigations are warranted to clarify these points. 
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Figure 1.  Chemical structures of 18F-FMISO and 18F-FRP170. 
 
 
 
 
 
 
 
 
 
 
 112
Figure 2.  A series of dynamic whole-body images of a 32-year-old male volunteer. 
 
 
 
  
Figure 3.  18F-FRP170 images of lung cancer (arrow) acquired 1 hr and 2hr after injection. 
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